Orchid Pharma Limited (ORCHPHARMA) - Total Assets
Based on the latest financial reports, Orchid Pharma Limited (ORCHPHARMA) holds total assets worth Rs19.11 Billion INR (≈ $206.66 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Orchid Pharma Limited (ORCHPHARMA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Orchid Pharma Limited - Total Assets Trend (2004–2026)
This chart illustrates how Orchid Pharma Limited's total assets have evolved over time, based on quarterly financial data. Check how high is Orchid Pharma Limited's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Orchid Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Orchid Pharma Limited's total assets of Rs19.11 Billion consist of 35.8% current assets and 64.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.4% |
| Accounts Receivable | Rs2.64 Billion | 13.8% |
| Inventory | Rs2.56 Billion | 13.4% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs736.76 Million | 3.9% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2004–2026)
This chart illustrates how Orchid Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Orchid Pharma Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orchid Pharma Limited's current assets represent 35.8% of total assets in 2026, a decrease from 36.8% in 2004.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2026, down from 0.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
Orchid Pharma Limited Competitors by Total Assets
Key competitors of Orchid Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Orchid Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.45 | 2.83 | 3.87 |
| Quick Ratio | 1.53 | 1.68 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.05 Billion | Rs5.22 Billion | Rs4.08 Billion |
Orchid Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Orchid Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 13.2% |
| Total Assets | Rs19.11 Billion |
| Market Capitalization | $574.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orchid Pharma Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Orchid Pharma Limited's assets grew by 13.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orchid Pharma Limited (2004–2026)
The table below shows the annual total assets of Orchid Pharma Limited from 2004 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs19.11 Billion ≈ $206.66 Million |
+13.21% |
| 2025-03-31 | Rs16.88 Billion ≈ $182.54 Million |
+8.63% |
| 2024-03-31 | Rs15.54 Billion ≈ $168.05 Million |
+26.83% |
| 2023-03-31 | Rs12.25 Billion ≈ $132.50 Million |
+10.32% |
| 2022-03-31 | Rs11.11 Billion ≈ $120.10 Million |
-10.24% |
| 2021-03-31 | Rs12.37 Billion ≈ $133.80 Million |
-15.25% |
| 2020-03-31 | Rs14.60 Billion ≈ $157.88 Million |
-52.55% |
| 2019-03-31 | Rs30.77 Billion ≈ $332.77 Million |
-1.55% |
| 2018-03-31 | Rs31.25 Billion ≈ $338.00 Million |
-4.00% |
| 2017-03-31 | Rs32.56 Billion ≈ $352.08 Million |
-15.70% |
| 2016-03-31 | Rs38.62 Billion ≈ $417.67 Million |
-4.91% |
| 2015-03-31 | Rs40.61 Billion ≈ $439.22 Million |
-12.68% |
| 2013-03-31 | Rs46.51 Billion ≈ $502.99 Million |
+16.67% |
| 2012-03-31 | Rs39.86 Billion ≈ $431.11 Million |
-2.07% |
| 2011-03-31 | Rs40.71 Billion ≈ $440.21 Million |
+7.87% |
| 2010-03-31 | Rs37.74 Billion ≈ $408.10 Million |
-10.87% |
| 2009-03-31 | Rs42.34 Billion ≈ $457.89 Million |
+21.52% |
| 2008-03-31 | Rs34.84 Billion ≈ $376.81 Million |
+20.52% |
| 2007-03-31 | Rs28.91 Billion ≈ $312.65 Million |
+33.32% |
| 2006-03-31 | Rs21.69 Billion ≈ $234.52 Million |
+19.64% |
| 2005-03-31 | Rs18.12 Billion ≈ $196.01 Million |
+26.94% |
| 2004-03-31 | Rs14.28 Billion ≈ $154.41 Million |
-- |
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more